Grand Pharmaceutical Group Limited

512 BMG210A71016

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 02:26:06 2024-07-18 EDT			5-day change	1st Jan Change
4.53 ^HKD	-1.09%		-4.82%	+11.00%

07-17	Grand Pharmaceutical Group Acquires Three Pharmaceutical Firms	MT
06-24	Grand Pharmaceutical Group Limited Announces Executive Changes	CI

China Grand Pharmaceutical and Healthcare Holdings Ltd. Announces Change of Principal Place of Business in Hong Kong

January 22, 2013 at 07:42 am

The board of the directors of China Grand Pharmaceutical and Healthcare Holdings Ltd. announced that the company's principal place of business in Hong Kong will be changed to Unit 3302, The Centre, 99 Queen's Road Central, Hong Kong with effect from January 23, 2013.

Latest news about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Acquires Three Pharmaceutical Firms	07-17	MT
Grand Pharmaceutical Group Limited Announces Executive Changes	06-24	CI
Grand Pharmaceutical Group Enrolls First Patient in Phase 1 Study for Myopia Eye Drops in China	06-12	MT
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment	06-11	CI
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	06-04	CI
Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	04-29	MT
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	03-27	CI
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug	03-24	MT
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors	03-24	CI
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024	03-19	CI
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication	03-08	MT
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial	03-08	MT
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884	03-07	CI
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China	02-08	MT
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator	01-24	MT
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan	01-16	MT
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops	12-27	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA	12-27	CI
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million	12-22	MT
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan	12-18	MT
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan	12-13	MT
Grand Pharmaceutical Unit Enrolls, Doses 1st Patient in Sepsis Drug Phase 2 Trial	11-27	MT
Grand Pharma Gets China's Nod for Phase 1 Clinical Trial for Tumor Vaccine	11-03	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01	11-02	CI

Chart Grand Pharmaceutical Group Limited

Duration

Period

Chart Grand Pharmaceutical Group Limited

More charts

Company Profile

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Grand Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.58 HKD

Average target price

5.4 HKD

Spread / Average Target

+17.90%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GRAND PHARMACEUTICAL GROUP LIMITED	+11.00%	2.05B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.64%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Grand Pharmaceutical Group Limited

Equities

512

BMG210A71016

Pharmaceuticals

China Grand Pharmaceutical and Healthcare Holdings Ltd. Announces Change of Principal Place of Business in Hong Kong

Latest news about Grand Pharmaceutical Group Limited

Chart Grand Pharmaceutical Group Limited

Company Profile

Income Statement Evolution

Ratings for Grand Pharmaceutical Group Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals